Dupont Capital Management’s Aimmune Therapeutics AIMT Stock Holding History

Dupont Capital Management’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-158,783	Closed	-$5.47M	–	1543
2020 Q3	$5.47M	Buy	+158,783	New	+$3.38M	0.12%	139

Dupont Capital Management's AIMT Position: Q4 2020 in Review

Dupont Capital Management sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 158,783 shares — an estimated $5.47M sold.

Dupont Capital Management first reported a position in AIMT in Q3 2020 and held it in 1 quarter. The position peaked at $5.47M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Dupont Capital Management reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Dupont Capital Management sold 158,783 Aimmune Therapeutics shares in Q4 2020, an estimated $5.47M.
Dupont Capital Management first reported a position in Aimmune Therapeutics in Q3 2020 and held it in 1 quarter.
Dupont Capital Management's Aimmune Therapeutics position peaked at $5.47M in Q3 2020.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Dupont Capital Management's 13F filing for Q4 2020, filed 28 Jan 2021.